This multicenter, prospective study aims to evaluate the real-world clinical utility of chest X-ray (CXR) for large-scale thoracic disease screening. Adult participants presenting for health examinations will undergo digital CXR screening, and any suspected abnormalities will be confirmed via a gold standard reference, such as a chest CT scan or clinical follow-up. The primary outcome measure is the detection rate (screening yield) of confirmed thoracic conditions. Secondary measures will assess diagnostic accuracy (sensitivity and specificity), false-positive rates, and multi-center reading consistency. By providing prospective, large-cohort evidence, this research seeks to validate the cost-effectiveness and feasibility of CXR in identifying early-stage lung, pleural, and cardiac abnormalities, ultimately guiding public health strategies and optimizing early medical intervention.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Age over 18.
* Ability to understand and willingness to sign a written informed consent form.
* Individuals presenting for routine health examinations or community-based screening.
Exclusion Criteria:
* Women who are pregnant, lactating, or planning to become pregnant during the study period.
* Physical limitations preventing stable positioning or breath-holding, or presence of metallic implants that may significantly degrade image quality.
* Known history of advanced thoracic diseases currently under treatment (e.g., active lung cancer, end-stage pulmonary fibrosis, or congestive heart failure).
* Individuals who have undergone chest CT or X-ray examinations within the past 3 months.
Primary outcome measure(s)
Overall Detection Rate of Thoracic Diseases — Through study completion, an average of 1 year. Defined as the proportion of subjects with positive X-ray findings that are subsequently confirmed by a gold standard reference (e.g., CT scan, pathology, or comprehensive clinical follow-up) out of the total screened population.
Screening Yield — Through study completion, an average of 1 year. Defined as the number of newly identified, clinically significant thoracic disease cases detected per 1,000 screening examinations.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.